Skip to main content
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2000 Aug;83(2):143–145. doi: 10.1136/adc.83.2.143

Intravenous pamidronate in juvenile osteoporosis

N Shaw 1, C Boivin 1, N Crabtree 1
PMCID: PMC1718443  PMID: 10906023

Abstract

AIMS—To investigate the use of the aminobisphosphonate, disodium pamidronate, in children with vertebral osteoporosis.
METHODS—Five children (aged 10-15 years) with vertebral osteoporosis who developed compression fractures in the thoracic and/or lumbar spine as a consequence of five different conditions, received treatment with intravenous disodium pamidronate in doses ranging from 0.5 to 12 mg/kg/y.
RESULTS—Each child had rapid pain relief following the first treatment, followed by large increments in lumbar spine bone density over one year; the change in bone density standard deviation score ranged from 0.5 to 2.5 with percentage increments of 26% to 54%.
CONCLUSION—Intravenous pamidronate appears to be a useful therapeutic option in childhood osteoporosis, but its use in children must still be regarded as experimental and therefore closely monitored.



Full Text

The Full Text of this article is available as a PDF (83.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi J. D., Bensen W. G., Brown J., Hanley D., Hodsman A., Josse R., Kendler D. L., Lentle B., Olszynski W., Ste-Marie L. G. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997 Aug 7;337(6):382–387. doi: 10.1056/NEJM199708073370603. [DOI] [PubMed] [Google Scholar]
  2. Adamson B. B., Gallacher S. J., Byars J., Ralston S. H., Boyle I. T., Boyce B. F. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet. 1993 Dec 11;342(8885):1459–1460. doi: 10.1016/0140-6736(93)92935-m. [DOI] [PubMed] [Google Scholar]
  3. Allgrove J. Biphosphonates. Arch Dis Child. 1997 Jan;76(1):73–75. doi: 10.1136/adc.76.1.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boot A. M., de Ridder M. A., Pols H. A., Krenning E. P., de Muinck Keizer-Schrama S. M. Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol Metab. 1997 Jan;82(1):57–62. doi: 10.1210/jcem.82.1.3665. [DOI] [PubMed] [Google Scholar]
  5. Brenner R. E., Vetter U., Bollen A. M., Mörike M., Eyre D. R. Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J Bone Miner Res. 1994 Jul;9(7):993–997. doi: 10.1002/jbmr.5650090706. [DOI] [PubMed] [Google Scholar]
  6. Brumsen C., Hamdy N. A., Papapoulos S. E. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997 Jul;76(4):266–283. doi: 10.1097/00005792-199707000-00005. [DOI] [PubMed] [Google Scholar]
  7. Eastell R., Reid D. M., Compston J., Cooper C., Fogelman I., Francis R. M., Hosking D. J., Purdie D. W., Ralston S. H., Reeve J. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. 1998 Oct;244(4):271–292. doi: 10.1046/j.1365-2796.1998.00408.x. [DOI] [PubMed] [Google Scholar]
  8. Glorieux F. H., Bishop N. J., Plotkin H., Chabot G., Lanoue G., Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998 Oct 1;339(14):947–952. doi: 10.1056/NEJM199810013391402. [DOI] [PubMed] [Google Scholar]
  9. Hoekman K., Papapoulos S. E., Peters A. C., Bijvoet O. L. Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab. 1985 Nov;61(5):952–956. doi: 10.1210/jcem-61-5-952. [DOI] [PubMed] [Google Scholar]
  10. Leong G. M., Mercado-Asis L. B., Reynolds J. C., Hill S. C., Oldfield E. H., Chrousos G. P. The effect of Cushing's disease on bone mineral density, body composition, growth, and puberty: a report of an identical adolescent twin pair. J Clin Endocrinol Metab. 1996 May;81(5):1905–1911. doi: 10.1210/jcem.81.5.8626856. [DOI] [PubMed] [Google Scholar]
  11. Lepore L., Pennesi M., Barbi E., Pozzi R. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol. 1991 Jan-Feb;9 (Suppl 6):33–35. [PubMed] [Google Scholar]
  12. Liens D., Delmas P. D., Meunier P. J. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet. 1994 Apr 16;343(8903):953–954. doi: 10.1016/s0140-6736(94)90069-8. [DOI] [PubMed] [Google Scholar]
  13. Nishioka T., Kurayama H., Yasuda T., Udagawa J., Matsumura C., Niimi H. Nasal administration of salmon calcitonin for prevention of glucocorticoid-induced osteoporosis in children with nephrosis. J Pediatr. 1991 May;118(5):703–707. doi: 10.1016/s0022-3476(05)80030-7. [DOI] [PubMed] [Google Scholar]
  14. Prentice A., Parsons T. J., Cole T. J. Uncritical use of bone mineral density in absorptiometry may lead to size-related artifacts in the identification of bone mineral determinants. Am J Clin Nutr. 1994 Dec;60(6):837–842. doi: 10.1093/ajcn/60.6.837. [DOI] [PubMed] [Google Scholar]
  15. Rogers J. G., Dorst J. P., Geho W. B. Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva. J Pediatr. 1977 Dec;91(6):1011–1014. doi: 10.1016/s0022-3476(77)80918-9. [DOI] [PubMed] [Google Scholar]
  16. Saggese G., Bertelloni S., Baroncelli G. I., Perri G., Calderazzi A. Mineral metabolism and calcitriol therapy in idiopathic juvenile osteoporosis. Am J Dis Child. 1991 Apr;145(4):457–462. doi: 10.1001/archpedi.1991.02160040119019. [DOI] [PubMed] [Google Scholar]
  17. Shaw N. J., White C. P., Fraser W. D., Rosenbloom L. Osteopenia in cerebral palsy. Arch Dis Child. 1994 Sep;71(3):235–238. doi: 10.1136/adc.71.3.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Shoemaker L. R. Expanding role of bisphosphonate therapy in children. J Pediatr. 1999 Mar;134(3):264–267. doi: 10.1016/s0022-3476(99)70447-6. [DOI] [PubMed] [Google Scholar]
  19. Smith R. Idiopathic juvenile osteoporosis: experience of twenty-one patients. Br J Rheumatol. 1995 Jan;34(1):68–77. doi: 10.1093/rheumatology/34.1.68. [DOI] [PubMed] [Google Scholar]
  20. Storm T., Thamsborg G., Steiniche T., Genant H. K., Sørensen O. H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990 May 3;322(18):1265–1271. doi: 10.1056/NEJM199005033221803. [DOI] [PubMed] [Google Scholar]
  21. van Persijn van Meerten E. L., Kroon H. M., Papapoulos S. E. Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology. 1992 Jul;184(1):249–254. doi: 10.1148/radiology.184.1.1609087. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES